Keryx Biopharmaceuticals Inc (KERX)

HEALTH CARE: PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS

ONE MARINA PARK DR. BOSTON, MA 02210

Acquires, develops and commercializes novel pharmaceutical products for the treatment of life-threatening diseases. As of Dec. 31, 2005, the company's lead product candidates were Sulonex for the treatment of diabetic nephropathy and KRX-0401 for the treatment of multiple forms of cancer.

Data based on most recent fiscal year report
Market Cap478.072 Million Shares Outstanding119.22 Million Avg Volume2.345 Million
1-Yr BETA vs S&P TR0.954 Current Ratio3.12 Quick Ratio2.49
View SEC Filings from KERX instead.
Q2 2018 All Institutions Hedge Funds 1
To trade KERX now:
Filers who had this stock in their top 10: 0 0 (0.0%)
13F Filers holding this stock: 126 21 (2.01%)
Aggregate 13F shares on 06/30/2018: 71.697 Million 38.517 Million
Aggregate 13F shares on 03/31/2018: 74.37 Million 37.931 Million
Percent change: -3.59% 1.54%
Funds creating new positions: 22 6
Funds Adding to an existing position: 39 7
Funds closing out their position: 15 4
Funds reducing their position: 32 3
1 hedge funds as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding KERX (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to

Exclude:

Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Acquired or Disposed Shares Owned Following Transaction Direct/Indirect Ownership
No current insider transactions
Click here to report any possible errors with this stock listing.

Elevate your investments